Grants Search Results

Neuroblastoma is the second most common solid cancer in childhood. Half of patients are at an advanced stage at diagnosis, difficult to treat successfully even with aggressive therapy. Ferritin is the body's storage form of iron, and elevated levels have been linked to worse outcomes in patients with neuroblastoma, but this phenomenon is still poorly understood. This research is investigating how genetic mutations in HFE, the gene responsible for the iron overload disorder, promote the development and spread of neuroblastoma cells. By identifying which specific iron metabolism pathways are involved, we can come up with new therapeutic strategies that are more specific and less toxic.

Osteosarcomas are a devastating pediatric bone cancer for which survival rates have not improved over 30 years. Current treatments remain aggressive and are prone to relapse. A new gene has been identified called Sox2, upon which osteosarcoma cells depend for survival. This project will evaluate whether strategies for blocking Sox2 function in tumors can eradicate the tumor and all residual cells to prevent relapse of the disease. These studies provide a novel basis for the targeted treatment of this childhood cancer and lead to a better understanding of the cancer stem cells that give rise to tumors.  

Bone marrow transplantation is an important and potentially curative treatment for children with relapsed leukemias. Infections due to a delay in the recovery of the immune system after transplantation are a major cause of complications and even death in these children. T-cells are a type of immune cells that fight infection. Of the various components of the immune system, the T-cells are the one that recover the poorest after bone marrow transplantation. The aim of this project is to understand how VEGF improves T cell production, with the ultimate goal of improving cure rates for children with relapsed leukemias.

Neuroblastoma is a cancer that develops in the nervous tissue and most cases occur in children younger than two years old. For patients with high-risk disease overall survival remains poor, thus there is a tremendous need to develop new treatments. This research improves the clinical development of a new drug, MLN 8237, which has shown promise in early pediatric clinical trials, and could improve survival in this devastating disease and provide additional targets for therapeutic intervention.

This institution is a member of a research consortium which is being funded by St. Baldrick's: the Pediatric Blood & Marrow Transplant Consortium. For a description of this project, "Innovative Pilot Trials in Pediatric HSCT for Malignancies-PBMTC Core Grant," see the consortium grant made to the lead institution: the National Marrow Donor Program, Minneapolis, MN.

This institution is a member of a research consortium which is being funded by St. Baldrick's: the Pediatric Blood & Marrow Transplant Consortium. For a description of this project, "Innovative Pilot Trials in Pediatric HSCT for Malignancies-PBMTC Core Grant," see the consortium grant made to the lead institution: the National Marrow Donor Program, Minneapolis, MN.

This institution is a member of a research consortium which is being funded by St. Baldrick's: the Pediatric Blood & Marrow Transplant Consortium. For a description of this project, "Innovative Pilot Trials in Pediatric HSCT for Malignancies-PBMTC Core Grant," see the consortium grant made to the lead institution: the National Marrow Donor Program, Minneapolis, MN.

This institution is a member of a research consortium which is being funded by St. Baldrick's: the Pediatric Blood & Marrow Transplant Consortium. For a description of this project, "Innovative Pilot Trials in Pediatric HSCT for Malignancies-PBMTC Core Grant," see the consortium grant made to the lead institution: the National Marrow Donor Program, Minneapolis, MN.

This institution is a member of a research consortium which is being funded by St. Baldrick's: the Pediatric Blood & Marrow Transplant Consortium. For a description of this project, "Innovative Pilot Trials in Pediatric HSCT for Malignancies-PBMTC Core Grant," see the consortium grant made to the lead institution: the National Marrow Donor Program, Minneapolis, MN.

This institution is a member of a research consortium which is being funded by St. Baldrick's: the Pediatric Blood & Marrow Transplant Consortium. For a description of this project, "Innovative Pilot Trials in Pediatric HSCT for Malignancies-PBMTC Core Grant," see the consortium grant made to the lead institution: the National Marrow Donor Program, Minneapolis, MN.

This institution is a member of a research consortium which is being funded by St. Baldrick's: the Pediatric Blood & Marrow Transplant Consortium. For a description of this project, "Innovative Pilot Trials in Pediatric HSCT for Malignancies-PBMTC Core Grant," see the consortium grant made to the lead institution: the National Marrow Donor Program, Minneapolis, MN.

This institution is a member of a research consortium which is being funded by St. Baldrick's: the Pediatric Blood & Marrow Transplant Consortium. For a description of this project, "Innovative Pilot Trials in Pediatric HSCT for Malignancies-PBMTC Core Grant," see the consortium grant made to the lead institution: the National Marrow Donor Program, Minneapolis, MN.

This institution is a member of a research consortium which is being funded by St. Baldrick's: the Pediatric Blood & Marrow Transplant Consortium. For a description of this project, "Innovative Pilot Trials in Pediatric HSCT for Malignancies-PBMTC Core Grant," see the consortium grant made to the lead institution: the National Marrow Donor Program, Minneapolis, MN.

This institution is a member of a research consortium which is being funded by St. Baldrick's: the Pediatric Blood & Marrow Transplant Consortium. For a description of this project, "Innovative Pilot Trials in Pediatric HSCT for Malignancies-PBMTC Core Grant," see the consortium grant made to the lead institution: the National Marrow Donor Program, Minneapolis, MN.

This institution is a member of a research consortium which is being funded by St. Baldrick's: the Texas-Oklahoma Pediatric Neuro-Oncology Consortium (TOPNOC). For a description of this project, "Comprehensive Studies of Pediatric CNS Tumors," see the consortium grant made to the lead institution: the Baylor College of Medicine, Texas Children's Hospital, Houston, TX.

This institution is a member of a research consortium which is being funded by St. Baldrick's: the New Approaches to Neuroblastoma Therapy (NANT) Consortium. For a description of this project, see the consortium grant made to the lead institution: the Children's Hospital Los Angeles, Los Angeles, CA.

This institution is a member of a research consortium which is being funded by St. Baldrick's: the New Approaches to Neuroblastoma Therapy (NANT) Consortium. For a description of this project, see the consortium grant made to the lead institution: the Children's Hospital Los Angeles, Los Angeles, CA.

This institution is a member of a research consortium which is being funded by St. Baldrick's: the Acute Lymphoblastic Leukemia Commitee of the Children's Oncology Group. For a description of this project, "Recurrence testing of new genomic lesions in childhood ALL," see the consortium grant made to the lead institution: the University of California, San Francisco, San Francisco, CA.

This institution is a member of a research consortium, the International Neuroblastoma Risk Group (INRG) Task Force, which is named for the “Just Do It…and be done with it” St. Baldrick’s Hero Fund created to celebrate the courage of cancer kids through treatment and the support of their family and friends. For a description of this project, see the consortium grant made to the lead institution: the University of Chicago, Chicago, IL.

This institution is a member of a research consortium which is being funded by St. Baldrick's: the Consortium for Pediatric Intervention Research. For a description of this project, "Pharmacologic prevention of heart failure in survivors of childhood cancer," see the consortium grant made to the lead institution: the Beckman Research Institute of the City of Hope, Duarte, CA. Year two of this grant was generously funded by the Rally Foundation.